Rangeley Capital’s Spero Therapeutics SPRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.8K Buy
+17,202
New +$23.3K 0.03% 129
2025
Q4
– Sell
-30,000
Closed -$56.4K – 156
2025
Q3
$56.4K Buy
+30,000
New +$66K 0.05% 117

Other funds holding SPRO

Rangeley Capital's SPRO Position: Q3 2026 in Review

Rangeley Capital opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 17,202 shares worth $20.8K. The stake represents 0.03% of the portfolio and ranks #129 among its holdings. This is a return to the name: Rangeley Capital previously reported a position in SPRO as recently as Q3 2025.

Rangeley Capital first reported a position in SPRO in Q3 2025 and has held it in 2 quarters since. The position peaked at $56.4K in Q3 2025. 61 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • Rangeley Capital held 17,202 shares of Spero Therapeutics worth $20.8K as of Q3 2026.
  • Spero Therapeutics was a new Rangeley Capital position in Q3 2026.
  • Spero Therapeutics made up 0.03% of Rangeley Capital's portfolio in Q3 2026, its #129 holding.
  • Rangeley Capital first reported a position in Spero Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Rangeley Capital's Spero Therapeutics position peaked at $56.4K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Rangeley Capital's 13F filing for Q3 2026, filed 16 Nov 2026.